ATE315039T1 - Multizyklische verbindungen und ihre verwendung als inhibitoren der parp, vegfr2 und mlk3 enzyme - Google Patents

Multizyklische verbindungen und ihre verwendung als inhibitoren der parp, vegfr2 und mlk3 enzyme

Info

Publication number
ATE315039T1
ATE315039T1 AT01935215T AT01935215T ATE315039T1 AT E315039 T1 ATE315039 T1 AT E315039T1 AT 01935215 T AT01935215 T AT 01935215T AT 01935215 T AT01935215 T AT 01935215T AT E315039 T1 ATE315039 T1 AT E315039T1
Authority
AT
Austria
Prior art keywords
vegfr2
parp
inhibitors
mlk3
enzymes
Prior art date
Application number
AT01935215T
Other languages
English (en)
Inventor
Mark A Ator
Ron Bihovsky
Sankar Chatterjee
Derek Dunn
Robert L Hudkins
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Application granted granted Critical
Publication of ATE315039T1 publication Critical patent/ATE315039T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
AT01935215T 2000-05-09 2001-05-09 Multizyklische verbindungen und ihre verwendung als inhibitoren der parp, vegfr2 und mlk3 enzyme ATE315039T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20294700P 2000-05-09 2000-05-09
US09/850,858 US7122679B2 (en) 2000-05-09 2001-05-08 Multicyclic compounds and the use thereof

Publications (1)

Publication Number Publication Date
ATE315039T1 true ATE315039T1 (de) 2006-02-15

Family

ID=26898160

Family Applications (3)

Application Number Title Priority Date Filing Date
AT01935215T ATE315039T1 (de) 2000-05-09 2001-05-09 Multizyklische verbindungen und ihre verwendung als inhibitoren der parp, vegfr2 und mlk3 enzyme
AT08075834T ATE482215T1 (de) 2000-05-09 2001-05-09 Multicyclische verbindungen und deren verwendung als inhibitoren der parp, vegfr2 und mlk3 enzyme
AT05076862T ATE411997T1 (de) 2000-05-09 2001-05-09 Multicyclische verbindungen und deren verwendung als inhibitoren der parp, vegfr2 und mlk3 enzyme

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT08075834T ATE482215T1 (de) 2000-05-09 2001-05-09 Multicyclische verbindungen und deren verwendung als inhibitoren der parp, vegfr2 und mlk3 enzyme
AT05076862T ATE411997T1 (de) 2000-05-09 2001-05-09 Multicyclische verbindungen und deren verwendung als inhibitoren der parp, vegfr2 und mlk3 enzyme

Country Status (27)

Country Link
US (1) US7122679B2 (de)
EP (3) EP2050750B1 (de)
JP (1) JP5156150B2 (de)
KR (1) KR100832602B1 (de)
CN (2) CN100554268C (de)
AT (3) ATE315039T1 (de)
AU (1) AU6132701A (de)
BG (1) BG66036B1 (de)
BR (1) BR0110993A (de)
CA (1) CA2409758A1 (de)
CY (1) CY1108722T1 (de)
CZ (2) CZ304911B6 (de)
DE (3) DE60143140D1 (de)
DK (1) DK1754707T3 (de)
EA (1) EA007868B1 (de)
ES (2) ES2256238T3 (de)
HU (1) HU229448B1 (de)
IL (1) IL152663A0 (de)
MX (1) MXPA02010977A (de)
NO (1) NO324256B1 (de)
NZ (1) NZ522539A (de)
PL (1) PL226805B1 (de)
PT (1) PT1754707E (de)
SK (1) SK287591B6 (de)
UA (1) UA73773C2 (de)
WO (1) WO2001085686A2 (de)
ZA (1) ZA200209065B (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6811992B1 (en) * 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
US20060276497A1 (en) * 2000-05-09 2006-12-07 Cephalon, Inc. Novel multicyclic compounds and the use thereof
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US20050070591A1 (en) * 2001-12-18 2005-03-31 Fumihiko Kanai Indole derivative
WO2003091255A1 (en) * 2002-04-26 2003-11-06 Warner-Lambert Company Llc Inhibitors of checkpoint kinases (wee1 and chk1)
US7094798B1 (en) 2002-04-26 2006-08-22 Pfizer Inc Inhibitors of checkpoint kinases (Wee1 and Chk1)
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7511065B2 (en) 2003-11-12 2009-03-31 Eli Lilly And Company Mixed lineage kinase modulators
CN1905864B (zh) * 2003-12-01 2011-04-06 库多斯药物有限公司 用于治疗癌症的dna损伤修复抑制剂
PL2305221T3 (pl) * 2003-12-01 2015-11-30 Kudos Pharm Ltd Inhibitory naprawy uszkodzeń DNA w leczeniu raka
PE20060285A1 (es) * 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
JP5070042B2 (ja) * 2004-05-03 2012-11-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 選択的アンドローゲン受容体モジュレーター（ｓａｒｍｓ）としての新規インドール化合物
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
US7820668B2 (en) 2005-01-19 2010-10-26 Eisai Inc. Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting PARP
ZA200800907B (en) * 2005-07-18 2010-04-28 Bipar Sciences Inc Treatment of cancer
CN102746229B (zh) * 2005-09-02 2015-04-08 大塚制药株式会社 制备苯并氮杂*化合物或其盐的方法
JP5227796B2 (ja) * 2005-09-29 2013-07-03 アボット・ラボラトリーズ ２位においてフェニルによって置換された１ｈ−ベンズイミダゾール−４−カルボキサミドは強力なｐａｒｐ阻害薬である
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
CN101534836B (zh) * 2006-09-05 2011-09-28 彼帕科学公司 Parp抑制剂在制备治疗肥胖症的药物中的用途
WO2008030883A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
WO2008030887A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Methods for designing parp inhibitors and uses thereof
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
TWI519313B (zh) * 2006-11-20 2016-02-01 希佛隆公司 使用放射敏感劑放射敏感化腫瘤之方法
US9061009B2 (en) * 2007-06-08 2015-06-23 University Of Massachusetts Mixed lineage kinases and metabolic disorders
MX2010002749A (es) 2007-09-14 2010-06-25 Astrazeneca Ab Derivados de ftalazinona.
ES2504690T3 (es) 2007-10-03 2014-10-08 Eisai Inc. Compuestos inhibidores de PARP, composiciones y métodos de uso
CN101903025A (zh) * 2007-10-19 2010-12-01 彼帕科学公司 利用苯并吡喃酮-型parp抑制剂治疗癌症的方法和组合物
EP2217244A4 (de) * 2007-11-12 2011-08-31 Bipar Sciences Inc Behandlung von gebärmutterkrebs und eierstockkrebs mit einem parp-inhibitor allein oder in kombination mit antitumoralen mitteln
US7732491B2 (en) * 2007-11-12 2010-06-08 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
RU2010128107A (ru) * 2007-12-07 2012-01-20 Байпар Сайенсиз, Инк. (Us) Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
MX2010008572A (es) * 2008-02-04 2010-11-30 Bipar Sciences Inc Metodos de diagnostico y tratamiento de enfermedades mediadas por poli(adp-ribosa) polimerasa.
JP2010006717A (ja) * 2008-06-24 2010-01-14 Kyorin Pharmaceut Co Ltd ジヒドロチエノ［２，３−ｅ］インダゾール化合物
CA2737400C (en) 2008-10-07 2016-11-22 Astrazeneca Uk Limited Pharmaceutical formulation 514
WO2010082813A1 (en) 2009-01-13 2010-07-22 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Method of treating cancer
MY156873A (en) 2009-08-26 2016-04-15 Cephalon Inc Novel forms of a multicyclic compound
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
WO2011077502A1 (ja) * 2009-12-21 2011-06-30 杏林製薬株式会社 ジヒドロチエノ［２，３－ｅ］インダゾール化合物
JP5699223B2 (ja) 2010-12-02 2015-04-08 シャンハイ デュァ ノボ ファルマテック カンパニー リミテッド 複素環誘導体、その合成法および医療用途
US9771325B2 (en) 2014-02-14 2017-09-26 Council Of Scientific & Industrial Research Tricyclic compounds and preparation thereof
WO2015121876A1 (en) * 2014-02-14 2015-08-20 Council Of Scientific & Industrial Research Novel tricyclic compounds and preparation thereof
BR112017010588A2 (pt) 2014-11-26 2018-05-15 Cephalon, Inc formas cristalinas de inibidores de parp
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
AU2016296905B2 (en) 2015-07-23 2018-07-05 Centre National De La Recherche Scientifique Use of a combination of Dbait molecule and parp inhibitors to treat cancer
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
WO2018022851A1 (en) 2016-07-28 2018-02-01 Mitobridge, Inc. Methods of treating acute kidney injury
RU2019114863A (ru) 2016-11-02 2020-12-03 Иммуноджен, Инк. Комбинированное лечение конъюгатами антитело-лекарственное средство и ингибиторами parp
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
WO2018197461A1 (en) 2017-04-28 2018-11-01 Akribes Biomedical Gmbh A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
CA3092779A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
US20220305048A1 (en) 2019-08-26 2022-09-29 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
GB201913030D0 (en) 2019-09-10 2019-10-23 Francis Crick Institute Ltd Treatment of hr deficient cancer
CN110862396B (zh) * 2019-11-29 2021-06-04 浙江工业大学 一种吡咯并[3,4-c]咔唑-1,3(2H，6H)-二酮类化合物的合成方法
JP7659560B2 (ja) 2019-12-16 2025-04-09 コリア リサーチ インスティチュート オブ ケミカル テクノロジー 新規なピリミジン誘導体及びその用途
AU2020406824A1 (en) 2019-12-16 2022-08-11 Korea Research Institute Of Chemical Technology Novel pyrimidine derivative and use thereof
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN113636970B (zh) * 2021-09-13 2023-05-23 河北康泰药业有限公司 一种异吲哚酮的化合物、制备方法及其应用
KR102939283B1 (ko) 2022-05-03 2026-03-13 한국화학연구원 5-클로로-2,4-다이아미노피리미딘을 포함하는 키나아제 억제 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
KR20240156074A (ko) 2023-04-21 2024-10-29 (주)엠디바이오팜 Hpk1 및 mlk3 저해제 및 이를 함유하는 항암용 조성물
CN121398822A (zh) 2023-06-21 2026-01-23 四方生物科学有限公司 用于在治疗hr功能正常的癌症的方法中的用途的包含脱氧胞苷衍生物和parp抑制剂的组合
KR20250041906A (ko) 2023-09-19 2025-03-26 (주)엠디바이오팜 Hpk1 및 mlk3 저해 활성을 갖는 신규한 화합물 및 이를 함유하는 항암용 조성물

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177075A (en) 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
DE3833008A1 (de) * 1988-09-29 1990-04-05 Goedecke Ag Pyrrolocarbozol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
US5166204A (en) 1989-11-01 1992-11-24 Toyama Chemical Co., Ltd. Isoindole derivatives and salts thereof and antitumor agent comprising the same
JP3025536B2 (ja) 1990-12-27 2000-03-27 富山化学工業株式会社 新規なカルバゾール誘導体およびその塩
CA2104873C (en) 1991-02-26 2000-05-23 James N. Campbell Compositions and methods of treatment of sympathetically maintained pain
US5298506A (en) * 1992-05-08 1994-03-29 Brigham And Women's Hospital Use of guanylate cyclase inhibitors in the treatment of shock
DE4217964A1 (de) * 1992-05-30 1993-12-02 Goedecke Ag Indolocarbazol-Imide und deren Verwendung
GB9319297D0 (en) * 1993-09-17 1993-11-03 Wellcome Found Indole derivatives
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
WO1995022331A1 (en) * 1994-02-18 1995-08-24 Cephalon, Inc. Aqueous indolocarbazole solutions
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
EP0695755B1 (de) 1994-08-04 1998-10-21 F. Hoffmann-La Roche AG Pyrrolocarbazol
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
EP0768311B1 (de) 1995-03-09 2003-08-06 Kyowa Hakko Kogyo Co., Ltd. Pyrrolocarbazolderivate
NZ333536A (en) * 1996-08-22 1999-10-28 Bristol Myers Squibb Co Cytotoxic amino sugar and related sugar derivatives of indolopyrrolocarbazoles, and use as antitumour agents
WO1998009967A1 (fr) 1996-09-09 1998-03-12 Kyowa Hakko Kogyo Co., Ltd. Derives de pyrrolocarbazole
AU8784698A (en) 1997-08-15 1999-03-08 Johns Hopkins University, The Method of using selective parp inhibitors to prevent or treat neurotoxicity
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
WO1999011622A1 (en) 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Amino-substituted compounds, methods, and compositions for inhibiting parp activity
US20020028813A1 (en) 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
WO1999011644A1 (en) 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
AU748887B2 (en) 1998-02-12 2002-06-13 Myriad Genetics, Inc. Beta-sheet mimetics and methods relating to the use thereof
ATE251624T1 (de) 1998-03-13 2003-10-15 Univ British Columbia Granulatimide-derivate zur behandlung von krebs
CA2332279A1 (en) 1998-05-15 1999-11-25 Jia-He Li Carboxamide compounds, compositions, and methods for inhibiting parp activity
AU9298798A (en) 1998-05-15 1999-12-06 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
US6063803A (en) * 1998-06-16 2000-05-16 Ortho-Mcneil Pharmaceutical, Inc. Octahydropyrrolo-[3,4-c]carbazoles useful as analgesic agents
JP2002523780A (ja) * 1998-08-26 2002-07-30 セフアロン・インコーポレーテツド 多系統キナーゼタンパク質の調節
US6841567B1 (en) * 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6399780B1 (en) * 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones

Also Published As

Publication number Publication date
WO2001085686A2 (en) 2001-11-15
SK287591B6 (sk) 2011-03-04
CZ304911B6 (cs) 2015-01-21
KR100832602B1 (ko) 2008-05-27
BR0110993A (pt) 2003-06-24
HK1051369A1 (en) 2003-08-01
PL363167A1 (en) 2004-11-15
EP1754707B1 (de) 2008-10-22
NO324256B1 (no) 2007-09-17
UA73773C2 (uk) 2005-09-15
DE60143140D1 (de) 2010-11-04
WO2001085686A3 (en) 2002-05-30
CA2409758A1 (en) 2001-11-15
NZ522539A (en) 2004-05-28
US7122679B2 (en) 2006-10-17
HUP0302385A3 (en) 2007-03-28
DK1754707T3 (da) 2008-12-15
EP2050750A3 (de) 2009-07-08
EA200201183A1 (ru) 2003-06-26
ES2256238T3 (es) 2006-07-16
EP2050750B1 (de) 2010-09-22
ES2315789T3 (es) 2009-04-01
HK1129381A1 (en) 2009-11-27
HU229448B1 (en) 2013-12-30
IL152663A0 (en) 2003-06-24
DE60116485D1 (de) 2006-03-30
CZ305350B6 (cs) 2015-08-12
CN100554268C (zh) 2009-10-28
ATE411997T1 (de) 2008-11-15
CN1440409A (zh) 2003-09-03
CN101560213B (zh) 2011-01-19
MXPA02010977A (es) 2003-07-14
HK1097841A1 (en) 2007-07-06
BG107355A (bg) 2003-07-31
BG66036B1 (bg) 2010-11-30
AU6132701A (en) 2001-11-20
EP1754707A2 (de) 2007-02-21
PT1754707E (pt) 2008-12-12
SK15802002A3 (sk) 2003-05-02
EP1294725A2 (de) 2003-03-26
CN101560213A (zh) 2009-10-21
EP1294725B1 (de) 2006-01-04
HUP0302385A2 (hu) 2003-12-29
DE60116485T2 (de) 2006-11-09
PL226805B1 (pl) 2017-09-29
EA007868B1 (ru) 2007-02-27
ZA200209065B (en) 2004-02-09
EP1754707A3 (de) 2007-02-28
CZ20023679A3 (cs) 2003-10-15
US20020028815A1 (en) 2002-03-07
DE60136305D1 (de) 2008-12-04
JP5156150B2 (ja) 2013-03-06
KR20030007603A (ko) 2003-01-23
NO20025376D0 (no) 2002-11-08
EP2050750A2 (de) 2009-04-22
CY1108722T1 (el) 2014-04-09
ATE482215T1 (de) 2010-10-15
NO20025376L (no) 2003-01-08
JP2004501097A (ja) 2004-01-15

Similar Documents

Publication Publication Date Title
DE60116485D1 (de) Multizyklische verbindungen und ihre verwendung als inhibitoren der parp, vegfr2 und mlk3 enzyme
WO2007149451A3 (en) Cycloalkanopyrrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors
CY1111086T1 (el) Παραγωγα 2-αμινο-κιναζολινης χρησιμα ως αναστολεις της βητα-σεκρετασης (bace)
ATE357272T1 (de) Verwendung von phthalazin-derivaten zur behandlung neurodegenerativer krankheiten
MA31167B1 (fr) Inhibiteurs de l'activite de akt
NO20060928L (no) Terapeutiske forbindelser
NO20081349L (no) Pyrrolopyrimidinderivater som Syk-inhibitorer
CY1109985T1 (el) Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων
DE602006021535D1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer-krankheit
PT1660507E (pt) Inibidores de proteassoma e seus métodos de utilização
ATE423087T1 (de) Proteasome inhibitoren und deren verwendung
CY1111070T1 (el) Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace)
BR9408025A (pt) Compostos de peptidila e seu uso terapêutico como inibidores de metaloproteinases
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
IL139826A0 (en) BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF IgE
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
DE602006020773D1 (de) Als inhibitoren von beta-sekretase (bace) geeignete 2-amino-3,4-dihydropyridoä3,4-düpyrimidinderivate
ATE448189T1 (de) Glycerin-peg-derivate als inhibitoren der cyclooxigenase-2 und der phospholipase-a2
ATE474047T1 (de) Nukleinsäuremolekül, die für die alpha-kettedes pferde-fc-epsilon-rezeptors kodieren, korrespondierende proteine und ihre verwendungen
DE50214750D1 (de) Kinase inhibitoren und deren verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1294725

Country of ref document: EP